Literature DB >> 15982347

Osteosclerosis in advanced chronic idiopathic myelofibrosis is associated with endothelial overexpression of osteoprotegerin.

Oliver Bock1, Gero Loch, Ulrika Schade, Guntram Büsche, Reinhard Wasielewski, Birgitt Wiese, Hans Kreipe.   

Abstract

Advanced chronic idiopathic myelofibrosis (IMF) with osteosclerosis and increase and thickening of bone trabeculae is typically contrasted by the absence or sparse presence of osteoclasts. Because osteoclast formation can be inhibited by osteoprotegerin (OPG) we investigated OPG expression in IMF with severe fibrosis and osteosclerosis, which expressed significantly higher (up to 71-fold) OPG mRNA levels when compared with prefibrotic cellular IMF and control cases. The receptor activator of nuclear factor kappaB ligand (RANKL), a positive regulator of osteoclast differentiation and putative antagonist of OPG was overexpressed by up to 34-fold exclusively in advanced IMF. Case-specific calculation of the RANKL/OPG ratio in advanced IMF showed a wide range without significant differences when compared with the prefibrotic IMF and non-neoplastic haematopoiesis. Immunohistochemical detection of OPG protein revealed strong labelling of endothelial cells within proliferating vessels in fibrotic IMF and heterogeneously labelled megakaryocytes, and fibroblasts. Osteosclerosis and impaired osteoclast function in IMF appears to be associated with upregulated endothelial OPG expression but concomitant reduction of the antagonist RANKL could not be demonstrated. We conclude that osteosclerosis in IMF is associated with increased endothelial OPG expression without concomitant RANKL downregulation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15982347     DOI: 10.1111/j.1365-2141.2005.05573.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  16 in total

1.  Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis.

Authors:  Lilian Varricchio; Annalisa Mancini; Anna Rita Migliaccio
Journal:  Expert Rev Hematol       Date:  2009-06-01       Impact factor: 2.929

2.  Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status.

Authors:  Oliver Bock; Johanne Neuse; Kais Hussein; Kai Brakensiek; Guntram Buesche; Thomas Buhr; Birgitt Wiese; Hans Kreipe
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

Review 3.  The bone marrow stroma in hematological neoplasms--a guilty bystander.

Authors:  Claudio Tripodo; Sabina Sangaletti; Pier P Piccaluga; Sonam Prakash; Giovanni Franco; Ivan Borrello; Attilio Orazi; Mario P Colombo; Stefano A Pileri
Journal:  Nat Rev Clin Oncol       Date:  2011-03-29       Impact factor: 66.675

4.  Myelofibrosis osteoclasts are clonal and functionally impaired.

Authors:  Ivo Veletic; Taghi Manshouri; Asha S Multani; C Cameron Yin; Lei Chen; Srdan Verstovsek; Zeev Estrov
Journal:  Blood       Date:  2019-02-11       Impact factor: 22.113

5.  Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells.

Authors:  Min Lu; Lijuan Xia; Yen-Chun Liu; Tsivia Hochman; Laetizia Bizzari; Daniel Aruch; Jane Lew; Rona Weinberg; Judith D Goldberg; Ronald Hoffman
Journal:  Blood       Date:  2015-05-28       Impact factor: 22.113

6.  Quantification of fibrosis and osteosclerosis in myeloproliferative neoplasms: a computer-assisted image study.

Authors:  Carolin J Teman; Andrew R Wilson; Sherrie L Perkins; Kimberly Hickman; Josef T Prchal; Mohamed E Salama
Journal:  Leuk Res       Date:  2010-01-31       Impact factor: 3.156

Review 7.  [Skeletal manifestations of systemic hematologic disorders].

Authors:  J Luitjens; A Baur-Melnyk
Journal:  Radiologe       Date:  2021-11-24       Impact factor: 0.635

8.  Increased skeletal VEGF enhances beta-catenin activity and results in excessively ossified bones.

Authors:  Christa Maes; Steven Goossens; Sonia Bartunkova; Benjamin Drogat; Lieve Coenegrachts; Ingrid Stockmans; Karen Moermans; Omar Nyabi; Katharina Haigh; Michael Naessens; Lieven Haenebalcke; Jan P Tuckermann; Marc Tjwa; Peter Carmeliet; Vice Mandic; Jean-Pierre David; Axel Behrens; Andras Nagy; Geert Carmeliet; Jody J Haigh
Journal:  EMBO J       Date:  2009-12-10       Impact factor: 11.598

Review 9.  Bone marrow niches in haematological malignancies.

Authors:  Simón Méndez-Ferrer; Dominique Bonnet; David P Steensma; Robert P Hasserjian; Irene M Ghobrial; John G Gribben; Michael Andreeff; Daniela S Krause
Journal:  Nat Rev Cancer       Date:  2020-02-28       Impact factor: 60.716

Review 10.  Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies.

Authors:  Abdallah Abou Zahr; Mohamed E Salama; Nicole Carreau; Douglas Tremblay; Srdan Verstovsek; Ruben Mesa; Ronald Hoffman; John Mascarenhas
Journal:  Haematologica       Date:  2016-06       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.